HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senator Seeks Trove Of Talc/Asbestos Docs From J&J; FDA On Status Of Lead Acetate Rule; Beauty News In Brief

Executive Summary

The Senate Health Committee’s ranking member is “troubled” by a recent Reuters article, requesting numerous documents from J&J related to talc-asbestos testing and the firm’s communications with FDA and consumers on the subject. More beauty news in brief.

You may also be interested in...



FDA May Put Hold On Lead Acetate Hair-Dye Rule; Manufacturer Combe Demands Hearing

Grecian Formula marketer Combe likens the process and calculations that informed FDA’s final rule against lead acetate to “a child’s game of telephone.” Environmental Defense Fund warns that if FDA grants Combe’s request – which the NGO suspects is unavoidable – it intends to cross-examine the company’s witnesses about consumer complaints and their handling in the firm’s past.

J&J CEO Sees Victory Ahead On Talc, Growth From Johnson's Relaunch

JP Morgan analysts had questions and J&J CEO Alex Gorsky and CFO Joseph Wolk had answers about liability suits alleging that use of the Johnson's brand talcum powder has caused mesothelioma or ovarian cancer. On the Johnson's brand outlook following its relaunch as a natural product line, Gorsky says sales were a key driver in the firm's consumer health sales in the 2018 third quarter. China, meanwhile, is a model for growing sales online, he says.

J&J Doing Damage Control Following Reuters Report On Asbestos ‘Lurking’ In Johnson’s Powder

J&J shares are down nearly 12% since Reuters reported Dec. 14 that the firm has known for decades about toxic asbestos in its Johnson’s Baby Powder talc. The news outlet’s probe turned up nothing that hasn’t been raised by plaintiff attorneys, but throws the central issues of contention into high relief for its global audience.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS148502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel